ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Sergio Garcia has been named Senior Vice President, General Counsel, and Corporate Secretary. With more than two decades of legal and compliance experience, Mr. Garcia brings a wealth of expertise and knowledge to ZELTIQ. Prior to joining ZELTIQ, Mr. Garcia was a partner at Reed Smith LLP and Fenwick & West LLP where he advised clients on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, public disclosure issues, and SEC reporting and compliance. He also served as outside general counsel to early-stage companies on intellectual property matters, strategic alliances, licensing and collaboration agreements, partnership agreements, financing, and litigation. Prior to that, Mr. Garcia played a key role as Vice President, Legal and General Counsel at PDL BioPharma Inc., where he acted as legal advisor to the executive management team and board of directors on a wide range of strategic and operational issues. “The breadth of Sergio’s legal expertise makes him an excellent addition to our executive leadership team,” said Gordie Nye, ZELTIQ president and chief executive officer. “Sergio has an impressive track record dealing in complex intellectual property matters and mergers and acquisitions. This, combined with his experience working with publicly-traded companies on general corporate matters and his understanding of medical device industry compliance, makes him an ideal addition to ZELTIQ.” About ZELTIQ ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.